+ -

University of Basel

22 July 2020

Spin-off: Bacterial cancer treatment on the path to enter clinical phase

Small glass bottles in a lab
Therapeutic candidate for bacterial cancer treatment (Photo: T3 Pharmaceuticals)

A spin-off of the University of Basel is breaking new ground in the treatment of cancer by using live bacteria. The closing of the third financing round allows the company T3 Pharmaceuticals AG to start clinical testing of their bacterial cancer therapy. The new funds amount to more than CHF 25 million.

To top